Modus Therapeutics AB, a Stockholm, Sweden-based company focused on innovative treatments for patients with sickle cell disease, completed a financing round of SEK 32m.
Backers included existing investors KDev Investments, part of Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital, Östersjöstiftelsen and Praktikerinvest.
Led by Christina Herder, CEO, Modus Therapeutics is a biotech company developing sevuparin – a new drug to treat people suffering from Sickle Cell Disease (SCD) – an inherited blood disorder affecting millions of people around the globe.
Sevuparin has the potential to improve the SCD patients’ blood flow reducing their pain and the amount of time they will need to spend in hospital.
The company plans to develop an administration form of sevuparin that the patient can self-administer allowing them to live a more normal life by preventing the painful episodes requiring hospital care. Modus is currently recruiting patients in Europe, the Middle East and Caribbean in an ongoing Phase II clinical study with sevuparin for sickle cell disease (SCD).
FinSMEs
21/02/2017